About Ambergen
Ambergen is a company based in United States founded in 1995. Ambergen has raised $5 million across 33 funding rounds from investors including Bruker and HHS. The company has 5 employees. Ambergen offers products and services including Miralys Probes, Miralys Panels, Miralys Kits, and MaxOmic Laboratory. Ambergen operates in a competitive market with competitors including BridgeBio, Guardant Health, Spark Therapeutics, Natera and Alnylam, among others.
- Headquarter United States
- Employees 5
- SectorsHealthcare
- Email••••••••
- Website ambergen.com
- Social LinkedIn
- Legal Name Ambergen Inc.
- Total Equity Funding$5M (USD)
in 33 rounds
- Latest Funding Round$1.99M (USD), Grant
Sep 2022
- InvestorsBruker
& 1 more
- Employee Count5
Products & Services of Ambergen
Ambergen offers a comprehensive portfolio of products and services, including Miralys Probes, Miralys Panels, Miralys Kits, and MaxOmic Laboratory.
Probes for photocleavable mass-tag imaging in spatial biology.
Panels for ultra-high-plex and rapid biological insights analysis.
Kits for labeling antibodies with mass-tags for research.
Services for multiomic spatial biology imaging and analysis.
Funding Insights of Ambergen
Ambergen has successfully raised a total of $5M across 33 strategic funding rounds. The most recent funding activity was a Grant round of $1.99 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 33
- Last Round Grant — $1.99M
- First Round $1.7M
(Mar 2004)
- Investors Count 2
Latest 10 of 33 funding rounds of Ambergen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Ambergen
Ambergen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Bruker and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Diversified research instrument systems are manufactured and supplied. | 1960 | bruker.com | United States |
Investor details for Ambergen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ambergen
5 people are tracked at Ambergen (2 in leadership, 3 in team); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
Gargey Yagnik | Principal Scientist and Director of Mass Spectrometry | Leadership |
John Gillespie | President & CEO | Leadership |
Andrew Yatsuhashi | Scientist II | Team |
Mark Lim | EVP & CSO | Team |
Shawn Carlson | Field Applications Engineer | Team |
Complete people profiles for Ambergen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ambergen
3 dated milestones of Ambergen across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Ambergen is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Grant, of $2.0M.
Competitors of Ambergen
Ambergen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Guardant Health, Spark Therapeutics, Natera and Alnylam, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Ambergen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ambergen
Websites that share an audience with Ambergen (ambergen.com).
Websites whose visitors overlap most with Ambergen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
nugeninc.com | nugeninc.com | 100% | – | – | – |
labnext.com | labnext.com | 100% | – | – | – |
| biocompanion.com | 100% | – | – | View details | |
| epigenomics.com | 100% | 2.4K | #6,675,395 | View details | |
| takara-bio.com | 100% | 4K | #4,713,078 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for Ambergen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Ambergen
10 companies that operate in the same segment as Ambergen (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ambergen
Ambergen was founded in 1995 and raised its 1st funding round 9 years after it was founded.
Ambergen is headquartered in United States.
Ambergen is a funded company, having raised a total of $5M across 33 funding rounds to date. The company's 1st funding round was a Grant of $5.53M, raised on Mar 2004.
Ambergen has 5 employees.
Developer of novel technology platforms for genomics, proteomics, and diagnostics. The companys technology portfolio includes Bead-GPS, which combines the advantages of MALDI mass spectrometric imaging (MALDI-MSI) and microarray technology for proteomic screening, LIVE-PRO cell-free expressed proteome bead-display platform, PC-LINKERS, collection of photocleavable compounds that can be manipulated using light, and others.
Ambergen's top competitors include Guardant Health, Spark Therapeutics and BridgeBio.
Ambergen offers Miralys Probes, Miralys Panels, Miralys Kits, and MaxOmic Laboratory.
Ambergen operates through Ambergen Inc..